|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2003-2-13
|
|
pubmed:abstractText |
Background and aims: Interferon (IFN) induced hepatitis B e antigen (HBeAg) seroconversion is durable in 80-90% of chronic hepatitis B patients. Preliminary reports on the durability of HBeAg seroconversion following lamivudine are contradictory. We investigated the durability of response following IFN, lamivudine, or IFN-lamivudine combination therapy in a meta-analysis of individual patient data.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/12584227-10051505,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12584227-10385662,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12584227-10462384,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12584227-10498663,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12584227-10528035,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12584227-10716688,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12584227-10889166,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12584227-11003626,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12584227-1380526,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12584227-15188197,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12584227-2003708,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12584227-2230128,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12584227-2680866,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12584227-3371868,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12584227-7538172,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12584227-7557849,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12584227-7814812,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12584227-8253359,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12584227-8618580,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12584227-8837608,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12584227-9096614,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12584227-9352870,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12584227-9362381,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12584227-9654535,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12584227-9672165,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12584227-9727065,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12584227-9854066,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12584227-9857348,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12584227-9869395
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0017-5749
|
|
pubmed:author |
pubmed-author:ChemelloLL,
pubmed-author:FontaineHH,
pubmed-author:HanselB CBC,
pubmed-author:HeathcoteJJ,
pubmed-author:JanssenH L AHL,
pubmed-author:LöhrH FHF,
pubmed-author:SchalmS WSW,
pubmed-author:SongB CBC,
pubmed-author:SuhD JDJ,
pubmed-author:de ManR ARA,
pubmed-author:van NunenA BAB
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
52
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
420-4
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:12584227-Adult,
pubmed-meshheading:12584227-Alanine Transaminase,
pubmed-meshheading:12584227-Antiviral Agents,
pubmed-meshheading:12584227-D-Alanine Transaminase,
pubmed-meshheading:12584227-DNA, Viral,
pubmed-meshheading:12584227-Drug Therapy, Combination,
pubmed-meshheading:12584227-Female,
pubmed-meshheading:12584227-Hepatitis B, Chronic,
pubmed-meshheading:12584227-Hepatitis B Antibodies,
pubmed-meshheading:12584227-Hepatitis B e Antigens,
pubmed-meshheading:12584227-Hepatitis B virus,
pubmed-meshheading:12584227-Humans,
pubmed-meshheading:12584227-Interferons,
pubmed-meshheading:12584227-Lamivudine,
pubmed-meshheading:12584227-Male,
pubmed-meshheading:12584227-Middle Aged,
pubmed-meshheading:12584227-Multivariate Analysis
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase.
|
|
pubmed:affiliation |
Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Centre Rotterdam, the Netherlands.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Meta-Analysis
|
